Medtronic just put about $700 million behind a second soft-tissue robot. On September 1 the company announced a strategic partnership with Hong Kong–based Cornerstone Robotics that includes distribution rights for Cornerstone’s Sentire surgical system in select markets outside the United States where Sentire is already approved. The pitch is not a consumer headset. It is an immersive dual-console OR stack sitting next to Medtronic’s own Hugo RAS system — and it is the clearest enterprise spatial-computing capital move of early September.
Per Medtronic’s September 1 release and Cornerstone’s matching PR Newswire note, the investment buys Medtronic the right to sell Sentire alongside Hugo. Medtronic frames the pair as a “two-platform portfolio” for hospitals that want choice across clinical settings and economic models. Global robotic-assisted surgery penetration is still in the single digits, Medtronic says; CEO Geoff Martha put emerging-market penetration at about 1% on the earnings call, according to MedTech Dive.
Why Sentire matters for XR readers
Medtronic’s own language is the hook. The release highlights Sentire’s “immersive console with dual-console capability” — a familiar surgeon-facing stereo workstation rather than a Quest-class HMD, but the same product thesis that shows up in Vision Pro OR apps and headset navigation systems: put depth, instruments, and team coordination inside one visual cockpit. Dual-console support is the training and teaching path. That is spatial computing sold as capital equipment, not as a storefront listing.
Sentire is Cornerstone’s full-stack endoscopic platform. It won China’s NMPA approval in 2024 and, in May 2026, CE Mark under MDR plus Singapore HSA clearance for minimally invasive general, gynecologic, thoracic, and urologic procedures. The U.S. is explicitly out of the distribution grant in this deal. Hugo remains Medtronic’s U.S. soft-tissue bet after its recent FDA clearance in urology; Medtronic has also filed 510(k)s to expand Hugo into general surgery and gynecology and has been pushing real-time AI through its Touch Surgery stack.
Hugo numbers Medtronic is defending
On the same announcement, Medtronic said Hugo is live in more than 35 countries across six continents, procedure growth is more than twice the broader robotic surgery market rate, and cumulative Hugo procedures should top 50,000 by fiscal year-end (MedTech Dive adds a target of about 250 installed units). Martha told investors the Cornerstone check is “just the opposite” of a lack of confidence in Hugo — a portfolio expansion, not a retreat.
The competitive field is tightening. Johnson & Johnson’s Ottava won FDA authorization in July, and Intuitive’s da Vinci still defines the category. Medtronic’s answer is to sell two multi-port soft-tissue platforms plus a connected digital ecosystem rather than a single SKU.
What is still unknown
Neither company disclosed ownership stake, exact distribution territories beyond “select markets outside the U.S. where the system is market approved,” or Sentire pricing. China, Singapore, and Europe are the markets MedTech Dive and TechNode Global associate with Sentire’s current approvals; treat that as the plausible map, not a confirmed exclusivity list. Advisors on the Medtronic side include Morgan Stanley and Cleary Gottlieb; Cornerstone lists Kirkland & Ellis and Global Law Office.
For Metaverse Watcher’s beat, the takeaway is capital flowing into immersive surgical consoles while consumer XR fights over glasses launch windows. The OR is buying stereo visualization and dual-operator workflows at nine-figure scale. Sentire is not a metaverse client. It is what enterprise spatial computing looks like when the buyer is a hospital system and the KPI is procedure volume.
Sources: Medtronic press release, Cornerstone / PR Newswire, MedTech Dive, TechNode Global.